HC Wainwright & Co. Initiates Coverage On TriSalus Life Sciences with Buy Rating, Announces Price Target of $11

Benzinga Newsdesk www.benzinga.com Neutral 54.7%

Neg 0% Neu 54.7% Pos 0%

HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and announces Price Target of $11.